Hansen, Aleksander L. http://orcid.org/0000-0002-9514-8942
Brøns, Charlotte http://orcid.org/0000-0002-6653-9020
Engelhard, Leonie M. http://orcid.org/0009-0008-9496-1297
Andersen, Mette K. http://orcid.org/0000-0001-8227-1469
Hansen, Torben http://orcid.org/0000-0001-8748-3831
Nielsen, Jens S. http://orcid.org/0000-0003-3179-1186
Vestergaard, Peter http://orcid.org/0000-0002-9046-2967
Højlund, Kurt http://orcid.org/0000-0002-0891-4224
Jessen, Niels http://orcid.org/0000-0001-5613-7274
Olsen, Michael H. http://orcid.org/0000-0003-2230-5780
Sørensen, Henrik T. http://orcid.org/0000-0003-4299-7040
Thomsen, Reimar W. http://orcid.org/0000-0001-9135-3474
Vaag, Allan http://orcid.org/0000-0002-3690-2191
Funding for this research was provided by:
Danish Agency for Science and Higher Education (09-067009, 09-075724)
Sundhedsstyrelsen
Region Syddanmark
Diabetesforeningen
Novo Nordisk Fonden (NNF17SA0030364, NNF17SA0030962-2, NNF18CC0034900, NNF20O0063292, NNF23SA0084103)
Lund University
Article History
Received: 21 November 2023
Accepted: 4 April 2024
First Online: 22 May 2024
Acknowledgements
: The authors are grateful to all participants in the DD2 study and to the healthcare personnel who recruited the participants at the general practices and outpatient clinics. The authors sincerely thank the DD2 management and DD2 data managers. An abstract version of this study was presented at the EASD 2023 annual meeting in Hamburg on 3 October 2023.
: Danish data protection legislation does not allow the authors to share any individual-level patient data. However, the Danish health registry data used in this study are accessible to researchers at authorised research institutions by application to the Danish Health Data Authority by email (forskerservice@sundhedsdata.dk). Requests to use data from the DD2 cohort can be made at the DD2 website ()
: Open access funding provided by Lund University. The DD2 study was supported by the Danish Agency for Science (grant numbers 09-067009 and 09-075724), the Danish Health and Medicines Authority, the Danish Diabetes Association, the Region of Southern Denmark and the Novo Nordisk Foundation (grant numbers NNF17SA0030962-2, NNF20O0063292, NNF17SA0030364, NNF18CC0034900 and NNF23SA0084103). Project partners are listed on the website. The study funders were not involved in the design of the study, the collection, analysis and interpretation of data or writing the report. They did not impose any restrictions regarding publication of the report.
: All authors have read and approved the manuscript. CB owns stock in Novo Nordisk. MHO has received payments or honoraria for lectures, presentations or educational events from AstraZeneca and Boehringer Ingelheim, has an unpaid position as chair of the Danish Hypertension Society and is a nucleus member of the Working Group for Prevention and Rehabilitation, Danish Society of Cardiology. The Department of Clinical Epidemiology, Aarhus University, receives funding for other studies in the form of institutional research grants to (and administered by) Aarhus University. None of these studies have any relation to the present study. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.
: AV conceived and designed the study and is the guarantor of the study. JSN is the principal manager of the Danish Centre for Strategic Research in Type 2 Diabetes (DD2). ALH performed the statistical analysis, prepared the first draft of the manuscript and revised the draft. All authors contributed to the interpretation of data and critically revised the content of the draft. AV, RWT and HTS supervised the study. All authors gave final approval of the version to be published. As such, they had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.